Baidu
map

ANN INTERN MED:2012年临床医学研究的重大研究成果

2013-04-22 ANN INTERN MED dxy

2012年陆续发表了一系列临床研究结果为临床医师提供了更好的临床实践参考。传统的临床检验,如前列腺特异性抗原(PSA)检测,常常存在是否用于所有患者临床筛查的的争议。这种争议往往不能得出明确的结论,但是去年的两项研究提供了这方面的证据,即PSA筛查对死亡率的影响较小,并且有造成重大伤害的风险。 一项新技术使结直肠癌患者的检测更为简便,而且有希望增加检出率。血栓栓塞性疾病的治疗有了重要的进展。新型

2012年陆续发表了一系列临床研究结果为临床医师提供了更好的临床实践参考。传统的临床检验,如前列腺特异性抗原(PSA)检测,常常存在是否用于所有患者临床筛查的的争议。这种争议往往不能得出明确的结论,但是去年的两项研究提供了这方面的证据,即PSA筛查对死亡率的影响较小,并且有造成重大伤害的风险。

一项新技术使结直肠癌患者的检测更为简便,而且有希望增加检出率。血栓栓塞性疾病的治疗有了重要的进展。新型抗凝剂,Xa因子抑制剂在未来几年或许会得到更广泛的使用。这些新型药物使得血栓性疾病的治疗更为简单有效。

去年两项新研究提示阿司匹林治疗可有效预防左心室功能障碍患者静脉血栓性(VTE)和卒中的复发。此外 一项新研究显示Bariatric减肥手术在治疗糖尿病方面有着深远影响,现在的问题是何时并如何推荐这种治疗方法。肥胖的新治疗包括美国FDA在2012年新批准的2种药物,但是临床医师在开此类药物之前应该仔细分析这些数据。

1、阿司匹林每天100 mg可以有效预防非肿瘤或心血管病患者特发性深静脉血栓的复发

Aspirin Reduces the Risk for Recurrent VTE After an Initial Unprovoked Deep Venous Thrombosis or Pulmonary Embolism

Becattini C, Agnelli G, Schenone A, et al. Aspirin for preventing the recurrence of venous thromboembolism.

2、口服Xa因子抑制剂利伐沙班与标准治疗方案(低分子量肝素加法华林)在治疗症状性肺栓塞上效果相当

Rivaroxaban, an Oral Factor Xa Inhibitor, Is Noninferior to Standard Treatment of Symptomatic Pulmonary Embolism

Bu¨ ller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.

3、华法林与阿司匹林在预防正常窦性心律心衰患者发生缺血性卒中、出血性卒中和死亡方面没有明显不同

No Difference Between Aspirin and Warfarin Anticoagulation for Patients With Heart Failure in Normal Sinus Rhythm

Homma S, Thompson JL, Pullicino PM, et al. Warfarin and aspirin in patients with heart failure and sinus rhythm.

4、不用泻药的CT仿真虚拟内镜诊断结肠腺瘤敏感性与特异性较高

Laxative-Free Computed Tomographic Colonography Approaches Colonoscopy Accuracy for Colorectal Cancer Screening

Zalis ME, Blake MA, Cai W, et al. Diagnostic accuracy of laxativefree computed tomographic colonography for detection of adenomatous adenomatous polyps in asymptomatic adults: a prospective evaluation.

5、PSA检测前列腺癌可降低前列腺相关的死亡但不能降低全因死亡率

Prostate Cancer Screening Reduces Prostate-Specific but Not All-Cause Mortality

Schro¨ der FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up.

6、局限性前列腺癌积极的手术治疗并不明显优于临床观察

Surgery for Localized Prostate Cancer Is Not Clearly Superior to Observation

Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versusobservation for localized prostate cancer.

7、美国FDA2012年批准替诺福韦加恩曲他滨用于HIV的暴露前预防

Preexposure Prophylaxis for HIV Prevention

Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.

8、联合应用芬特明/托吡酯或可有效降低体重

Combination Phentermine–Topiramate May Be Effective for Weight Loss

Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.

9、减肥手术相比非手术治疗2型糖尿病更有效

Bariatric Surgery Is More Effective Than Nonsurgical Treatment for Controlling Type 2 Diabetes

Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes.

原文阅读:Update in general internal medicine: evidence published in 2012.

This Update summarizes studies published in 2012 that the authors consider highly relevant to the practice of general internal medicine. Topics include venous thromboembolism, colorectal cancer screening, prostate cancer, HIV infection, and obesity.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1898369, encodeId=84b7189836927, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sat Jul 06 12:40:00 CST 2013, time=2013-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754966, encodeId=e2591e5496603, content=<a href='/topic/show?id=ec5995e752e' target=_blank style='color:#2F92EE;'>#重大研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95775, encryptionId=ec5995e752e, topicName=重大研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb4036811817, createdName=zz12341246, createdTime=Sun Feb 16 11:40:00 CST 2014, time=2014-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543577, encodeId=03fc15435e73c, content=<a href='/topic/show?id=509b3418366' target=_blank style='color:#2F92EE;'>#医学研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34183, encryptionId=509b3418366, topicName=医学研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4b713593170, createdName=ms1065684921169360, createdTime=Wed Apr 24 06:40:00 CST 2013, time=2013-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605924, encodeId=8dc316059241a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Apr 24 06:40:00 CST 2013, time=2013-04-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1898369, encodeId=84b7189836927, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sat Jul 06 12:40:00 CST 2013, time=2013-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754966, encodeId=e2591e5496603, content=<a href='/topic/show?id=ec5995e752e' target=_blank style='color:#2F92EE;'>#重大研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95775, encryptionId=ec5995e752e, topicName=重大研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb4036811817, createdName=zz12341246, createdTime=Sun Feb 16 11:40:00 CST 2014, time=2014-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543577, encodeId=03fc15435e73c, content=<a href='/topic/show?id=509b3418366' target=_blank style='color:#2F92EE;'>#医学研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34183, encryptionId=509b3418366, topicName=医学研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4b713593170, createdName=ms1065684921169360, createdTime=Wed Apr 24 06:40:00 CST 2013, time=2013-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605924, encodeId=8dc316059241a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Apr 24 06:40:00 CST 2013, time=2013-04-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1898369, encodeId=84b7189836927, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sat Jul 06 12:40:00 CST 2013, time=2013-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754966, encodeId=e2591e5496603, content=<a href='/topic/show?id=ec5995e752e' target=_blank style='color:#2F92EE;'>#重大研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95775, encryptionId=ec5995e752e, topicName=重大研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb4036811817, createdName=zz12341246, createdTime=Sun Feb 16 11:40:00 CST 2014, time=2014-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543577, encodeId=03fc15435e73c, content=<a href='/topic/show?id=509b3418366' target=_blank style='color:#2F92EE;'>#医学研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34183, encryptionId=509b3418366, topicName=医学研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4b713593170, createdName=ms1065684921169360, createdTime=Wed Apr 24 06:40:00 CST 2013, time=2013-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605924, encodeId=8dc316059241a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Apr 24 06:40:00 CST 2013, time=2013-04-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1898369, encodeId=84b7189836927, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sat Jul 06 12:40:00 CST 2013, time=2013-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754966, encodeId=e2591e5496603, content=<a href='/topic/show?id=ec5995e752e' target=_blank style='color:#2F92EE;'>#重大研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95775, encryptionId=ec5995e752e, topicName=重大研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb4036811817, createdName=zz12341246, createdTime=Sun Feb 16 11:40:00 CST 2014, time=2014-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543577, encodeId=03fc15435e73c, content=<a href='/topic/show?id=509b3418366' target=_blank style='color:#2F92EE;'>#医学研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34183, encryptionId=509b3418366, topicName=医学研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4b713593170, createdName=ms1065684921169360, createdTime=Wed Apr 24 06:40:00 CST 2013, time=2013-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605924, encodeId=8dc316059241a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Apr 24 06:40:00 CST 2013, time=2013-04-24, status=1, ipAttribution=)]

相关资讯

2012年度中国高校十大科技进展揭晓

2012年度“中国高等学校十大科技进展”在12月18日举行的教育部科学技术委员会全会上揭晓。 2012年度高校这十大科技进展是:安徽医科大学主持的全基因组外显子测序分析发现汗孔角化症、掌跖角化症和少毛症致病基因研究, 北京大学主持的强激光场下原子分子隧道电离研究,哈尔滨工业大学主持的先进微小卫星平台技术研究,兰州大学主持的牦牛基因组及对高海拔的生命适应研究,清 华大学主持的脑起搏器研究,武汉

2012中国科技论文统计结果 临床医学论文最多

根据《中国科技期刊引证报告》结果,2011年,我国科研人员共发表国际论文14.36万篇(未统计港澳地区),排名世界第2,仅次于美国 (41.94万篇)。其中,“表现不俗”的论文(指被引用次数高于国际平均水平)为42927篇,占总数的29.8%,较2010年上升了10个百分点。 其中,生物、临床医学、基础医学、药学等10个学科表现不俗的论文数量最多。表现不俗的论文发表数量排名前5位的医疗机构依次

MedSci点评:2012年十大具有启示性的研究成果

Cell:硫利达嗪成功消灭人体白血病干细胞 MedSci点评:可能很多读者并不在意这一研究,因为有关肿瘤干细胞的研究实在太多了。但是这却是唯一从传统化学药物中发现具有靶向肿瘤干细胞的 药物,这为靶向肿瘤干细胞提供新的契机。虽然目前还不能找到所谓的肿瘤干细胞专属markers,但是从小分子中筛选有效药物,却是重要的途径。硫利达嗪可能为肿瘤干细胞靶向小分子药物提供一个思路,也值得深入探究其中的分子

ASCO发布2012年度肿瘤临床研究进展报告(下)

上部分见: ASCO发布2012年度肿瘤临床研究进展报告(上)妇科肿瘤 重大进展:JCO:贝伐单抗对复发性卵巢癌有益 摘要:Ⅲ期AURELIA研究显示,对曾接受含铂类化疗的卵巢癌患者,与单纯化疗相比,选择性标准化疗(聚乙二醇脂质体多柔比星、拓扑替康或紫杉醇每周方案)联合贝伐珠单抗,可显著延长患者中位TTP。 推荐原文:Gordon AN, Fleagle JT, Guthrie D, e

盘点2012年中国学者发表的SCI论文

截止到2012年12月26日,共进入数据库的发表论文数量为1182810篇。分析文献类型=(ARTICLE OR LETTER OR PROCEEDINGS PAPER OR EDITORIAL MATERIAL OR REVIEW)。118万篇论文中,其中发表数量前10名的国家如下。比较突出的特点是中国大陆学者发表的论文数量首次超过美国总数的50%,而且几乎是第3和4名两个国家的总数,比较有意思

ASCO发布2012年度肿瘤临床研究进展报告(上)

自2004年以来,连续8年美国临床肿瘤学会(ASCO)都会对癌症领域的突出临床研究进展进行回顾,发布年度报告。2012年的ASCO临床研究进展报告共包括87项研究,其中17项为主要进展,其余为显著进展。 其完整报告下载请见:http://download.bioon.com.cn/detail.php?id=6EF36259-2EBB-46B8-AEAD-1111b7974FFA 目录: 血

Baidu
map
Baidu
map
Baidu
map